STA
ARRY

Summit Trail Advisors’s Array Biopharma Inc ARRY Stock Holding History

Summit Trail Advisors’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-4,930
Closed -$83K – 506
2018
Q2 		$83K Buy
+4,930
New +$78.4K 0.03% 240
2018
Q1 		– Sell
-5,820
Closed -$82K – 2011
2017
Q4 		$82K Buy
+5,820
New +$66.2K 0.01% 685

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Summit Trail Advisors's ARRY Position: Q3 2018 in Review

Summit Trail Advisors sold out of Array Biopharma Inc (ARRY) in Q3 2018, closing a stake of 4,930 shares — an estimated $83K sold.

Summit Trail Advisors first reported a position in ARRY in Q4 2017 and held it in 2 quarters. The position peaked at $83K in Q2 2018. 208 funds tracked by Wall St. Rank hold ARRY as of Q3 2018.

  • Summit Trail Advisors reported no remaining Array Biopharma Inc position as of Q3 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 4,930 Array Biopharma Inc shares in Q3 2018, an estimated $83K.
  • Summit Trail Advisors first reported a position in Array Biopharma Inc in Q4 2017 and held it in 2 quarters.
  • Summit Trail Advisors's Array Biopharma Inc position peaked at $83K in Q2 2018.
  • 208 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2018.

Based on Summit Trail Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.